WST (West Pharmaceutical Services) 3-Year Sharpe Ratio : -0.23 (As of Jul. 05, 2025)

View and export this data going back to 1973. Start your Free Trial

What is West Pharmaceutical Services 3-Year Sharpe Ratio?

The 3-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past three years. As of today (2025-07-05), West Pharmaceutical Services's 3-Year Sharpe Ratio is -0.23.

Competitive Comparison of West Pharmaceutical Services's 3-Year Sharpe Ratio

For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's 3-Year Sharpe Ratio, along with its competitors' market caps and 3-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

West Pharmaceutical Services's 3-Year Sharpe Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's 3-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where West Pharmaceutical Services's 3-Year Sharpe Ratio falls into.

Save Embed

;

Save Embed

;

West Pharmaceutical Services 3-Year Sharpe Ratio Calculation

The 3-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last three years. A stock / portfolio's 3-Year Sharpe Ratio can be calculated by dividing the difference between the three-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past three years.

West Pharmaceutical Services (NYSE:WST) 3-Year Sharpe Ratio Explanation

The 3-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past three years. It is calculated as the annualized result of the average three-year monthly excess returns divided by its standard deviation in the three-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

West Pharmaceutical Services 3-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of West Pharmaceutical Services's 3-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

West Pharmaceutical Services Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » West Pharmaceutical Services Inc (NYSE:WST) » Definitions » 3-Year Sharpe Ratio

Comparable Companies

Traded in Other Exchanges

WST:Mexico WPS:Germany WPS:Germany W2ST34:Brazil

Address

530 Herman O. West Drive, Exton, PA, USA, 19341-1147

Website

https://www.westpharma.com

West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

Executives

Charles Witherspoon	officer: VP & Treasurer	530 HERMAN O WEST DRIVE, EXTON PA 19341
Eric Mark Green	officer: Chief Executive Officer	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Silji Abraham	officer: Chief Digital & Trans Officer	5000 TOWN CENTER, U, SOUTHFIELD MI 48075
Thomas W Hofmann	director	FIVE RADNOR CORPORATE CENTER, SUITE 500, RADNOR PA 19087
Chad Winters	officer: VP, CAO & Controller	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Annette F Favorite	officer: Sr. VP Human Resources Officer	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Cindy Reiss-clark	officer: Senior Vice President	530 HERMAN O. WEST DRIVE, EXTON PA 19341-1147
Quintin J Lai	officer: VP Corp Development & Strategy	530 HERMAN 0. WEST DRIVE, EXTON PA 19341
Bernard Birkett	officer: Sr VP, CFO & Treasurer	1600 WEST MERIT PARKWAY, SOUTH JORDAN UT 84095
Stephen H Lockhart	director	C/O NATIONAL RESEARCH CORPORATION, 1245 Q STREET, LINCOLN NE 68508
Molly Joseph	director	9209 GRAND SUMMIT BLVD, DRIPPING SPRINGS TX 78620
Kimberly Banks Mackay	officer: SVP, GC & Corporate Secretary	530 HERMAN O. WEST DRIVE, EXTON PA 19341
George Lloyd Miller	officer: Sr. VP, GC & Corp. Sec.	530 HERMAN O. WEST DRIVE, EXTON PA 19341
David A Montecalvo	officer: SVP, Glob Ops and Supply Chain	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Robert F Friel	director	940 WINTER STREET, WALTHAM MA 02451